The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis

Liping Qiu(Second Affiliated Hospital of Zhejiang University), Xiaoying Zhao(Handan College), Hanlu Zheng(Second Affiliated Hospital of Zhejiang University)
BMC Cancer
March 27, 2019
10.1186/s12885-019-5466-y
Cited by 49

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2013|247
Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis
|BMC Cancer|2014|146
Systemic Lupus Erythematous and Malignancy Risk: A Meta-Analysis
|PLoS ONE|2015|115